1. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- Author
-
Marcia Belvin, Stephen E. Gould, Peter J.R. Ebert, Jeong M. Kim, Jeanne Cheung, Erin McNamara, Marina Moskalenko, Rebecca Hong, Bryan Irving, Yagai Yang, Heather Maecker, and Ira Mellman
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,Cell cycle checkpoint ,T cell ,Immunology ,Priming (immunology) ,Apoptosis ,CD8-Positive T-Lymphocytes ,Biology ,Lymphocyte Activation ,B7-H1 Antigen ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Drug Therapy ,Piperidines ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Immunology and Allergy ,Cytotoxic T cell ,Molecular Targeted Therapy ,Extracellular Signal-Regulated MAP Kinases ,Protein kinase A ,Mice, Inbred BALB C ,Kinase ,Carcinoma ,Antibodies, Monoclonal ,Drug Synergism ,Cell Cycle Checkpoints ,030104 developmental biology ,Infectious Diseases ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Colonic Neoplasms ,Cancer research ,Azetidines ,Drug Therapy, Combination ,Immunotherapy ,Neoplasm Transplantation ,CD8 - Abstract
Targeted inhibition of mitogen-activated protein kinase (MAPK) kinase (MEK) can induce regression of tumors bearing activating mutations in the Ras pathway but rarely leads to tumor eradication. Although combining MEK inhibition with T-cell-directed immunotherapy might lead to more durable efficacy, T cell responses are themselves at least partially dependent on MEK activity. We show here that MEK inhibition did profoundly block naive CD8(+) T cell priming in tumor-bearing mice, but actually increased the number of effector-phenotype antigen-specific CD8(+) T cells within the tumor. MEK inhibition protected tumor-infiltrating CD8(+) T cells from death driven by chronic TCR stimulation while sparing cytotoxic activity. Combining MEK inhibition with anti-programmed death-ligand 1 (PD-L1) resulted in synergistic and durable tumor regression even where either agent alone was only modestly effective. Thus, despite the central importance of the MAP kinase pathway in some aspects of T cell function, MEK-targeted agents can be compatible with T-cell-dependent immunotherapy.
- Published
- 2016